|
|
Analysis of ATP-Binding Cassette Transporter Expression in Drug-Selected
Cell Lines by a Microarray Dedicated to Multidrug Resistance.
Annereau JP, Szakacs G, Tucker CJ, Arciello A, Cardarelli C, Collins J,
Grissom S, Zeeberg BR, Reinhold W, Weinstein JN, Pommier Y, Paules RS, and Gottesman MM
Mol Pharmacol. 2004 Dec;66(6):1397-405. Epub 2004 Sep 01.
 |
 |
Abstract:
Discovery of the multidrug resistance protein 1 (MDR1), an ATP-binding cassette (ABC) transporter
able to transport many anticancer drugs, was a clinically relevant breakthrough in multidrug
resistance research. Although the overexpression of ABC transporters such as P-glycoprotein/ABCB1,
MRP1/ABCC1, and MXR/ABCG2 seems to be a major cause of failure in the treatment of cancer, acquired
resistance to multiple anticancer drugs may also be multifactorial, involving alteration of
detoxification processes, apoptosis, DNA repair, drug uptake, and overexpression of other ABC
transporters. As a tool for the study of such phenomena, we designed and created a microarray
platform, the ABC-ToxChip, to evaluate relative levels of transcriptional activation among genes
involved in the various mechanisms of resistance. In the ABC-ToxChip, a comprehensive set of genes
important in toxicological responses (represented by 2200 cDNA probes) is complemented with probes
specifically matching ABC transporters as well as oligonucleotides representing 18,000 unique human
genes. By comparing the transcriptional profiles of KB-3-1 and DU-145 parental cells with resistant
derivatives selected in colchicine (KB-8-5), and 9-nitro-camptothecin (RCO.1), respectively, we
demonstrate that ABC transporters (ABCB1/MDR1 and ABCC2/MRP2, respectively) show dramatic overexpression,
whereas the glutathione S-transferase gene GST-Pi shows the strongest decrease in expression among
the 20,000 genes studied. The results were confirmed by quantitative reverse transcription-polymerase
chain reaction and immunohistochemistry. The custom-designed ABC-Tox microarray presented here will
be helpful to elucidate mechanisms leading to anticancer drug resistance.
|